Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.

Warrior Met Coal, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (NYSE:HCC) (WARRIOR OR THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED A REGULAR QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE TO BE PAID ON AUGUST 15, 2025, TO STOCKHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON AUGUST 8, 2025. ABOUT WARRIOR WARRIOR IS A U.S.-BASED, ENVIRONMENTALLY, AND SOCIALLY MINDED SUPPLIER TO THE GLOBAL STEEL INDUSTRY. IT IS DEDICATED ENTIRELY TO MINING NON-THERMAL METALLURGICAL (MET) COAL U.

WARRIOR ANNOUNCES REGULAR QUARTERLY CASH DIVIDEND

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (WARRIOR OR NYSE: HCC) TODAY ANNOUNCED THAT IT WILL HOLD ITS SECOND QUARTER 2025 INVESTOR CONFERENCE CALL AT 4:30 P.M. ET ON WEDNESDAY, AUGUST 6, 2025. WARRIOR WILL RELEASE ITS RESULTS FOLLOWING THE CLOSE OF MARKET TRADING THAT AFTERNOON. TO PARTICIPATE IN THE CONFERENCE CALL, PLEASE CALL 1-844-340-9047 (DOMESTIC) OR 1-412-858-5206 (INTERNATIONAL) 10 MINUTES PRIOR TO THE START TIME AND REFERENCE THE WARRIOR MET COAL CONFERENCE CALL. A W.

WARRIOR SETS DATE FOR SECOND QUARTER 2025 EARNINGS ANNOUNCEMENT AND INVESTOR CONFERENCE CALL

BRISBANE, CALIF., JUNE 30, 2025 (GLOBE NEWSWIRE) -- TEMPEST THERAPEUTICS, INC. (NASDAQ: TPST), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY WITH A PIPELINE OF FIRST-IN-CLASSI TARGETED AND IMMUNE-MEDIATED THERAPEUTICS TO FIGHT CANCER, TODAY ANNOUNCED THAT THE COMPANY RECEIVED APPROVAL FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN CHINA TO PROCEED WITH A PIVOTAL TRIAL TO EVALUATE AMEZALPAT (TPST-1120) IN COMBINATION WITH ATEZOLIZUMAB AND BEVACIZUMAB, THE CURRENT STANDARD OF CARE, VERSUS THE STANDARD OF CARE ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC).

TEMPEST RECEIVES CLEARANCE TO PROCEED WITH PIVOTAL TRIAL OF AMEZALPAT COMBINATION THERAPY FOR FIRST-LINE HCC IN CHINA

EMA ORPHAN DRUG DESIGNATION (ODD) BUILDS ON U.S. FOOD & DRUG ADMINISTRATION (FDA) ODD AND FAST TRACK DESIGNATION, UNDERSCORING THE URGENT NEED FOR NEW TREATMENT OPTIONS THE MULTIPLE REGULATORY DESIGNATIONS WERE GRANTED FOLLOWING STRONG POSITIVE RESULTS FROM A GLOBAL RANDOMIZED PHASE 1B/2 STUDY IN FIRST-LINE HCC DEMONSTRATING SUPERIOR OUTCOMES FOR AMEZALPAT COMBINATION THERAPY ACROSS MULTIPLE STUDY ENDPOINTS, INCLUDING OVERALL SURVIVAL IN BOTH THE ENTIRE POPULATION AND KEY SUBPOPULATIONS, WHEN COMPARED TO STANDARD OF CARE ALONE BRISBANE, CALIF., JUNE 05, 2025 (GLOBE NEWSWIRE) -- TEMPEST THERAPEUTICS, INC. (NASDAQ: TPST), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY WITH A PIPELINE OF FIRST-IN-CLASS1 TARGETED AND IMMUNE-MEDIATED THERAPEUTICS TO FIGHT CANCER, TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION (ODD) TO AMEZALPAT (TPST-1120), AN ORAL, SMALL MOLECULE, SELECTIVE PPAR ANTAGONIST FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC).

TEMPEST RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR AMEZALPAT FOR THE TREATMENT OF PATIENTS WITH HCC

THIS CAMPAIGN AIMS TO RAISE AWARENESS OF THE HIGH-QUALITY CARE AND SERVICES PROVIDED BY SUSAN G. KOMEN TO IMPROVE AND SAVE THE LIVES OF THOSE IMPACTED BY BREAST CANCER THIS CAMPAIGN AIMS TO RAISE AWARENESS OF THE HIGH-QUALITY CARE AND SERVICES PROVIDED BY SUSAN G. KOMEN TO IMPROVE AND SAVE THE LIVES OF THOSE IMPACTED BY BREAST CANCER

TOKIO MARINE HCC AND SUSAN G. KOMEN TEAM UP ONCE AGAIN WITH GOLF CHAMPION NELLY KORDA TO HELP END BREAST CANCER

PITTSBURGH--(BUSINESS WIRE)-- #INNOVATION--SOMERSET INTERNATIONAL HAS SUCCESSFULLY DEPLOYED SIX STATE-OF-THE-ART TAILINGS DEWATERING SYSTEMS AT WARRIOR MET COAL'S BLUE CREEK MINE.

SOMERSET INTERNATIONAL INSTALLS SIX TAILINGS DEWATERING UNITS AT WARRIOR MET COAL'S BLUE CREEK MINE, THE LARGEST U.S. COAL FACILITY WITHOUT A TAILINGS DAM

MORRISTOWN, N.J., MAY 07, 2025 (GLOBE NEWSWIRE) -- HEPION PHARMACEUTICALS, INC. (NASDAQ:HEPA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY THAT HAD BEEN DEVELOPING A TREATMENT FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATOCELLULAR CARCINOMA (HCC), AND OTHER CHRONIC LIVER DISEASES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A BINDING LETTER OF INTENT (LOI) WITH NEW DAY DIAGNOSTICS LLC TO IN-LICENSE DIAGNOSTIC TESTS FOR CELIAC DISEASE, RESPIRATORY MULTIPLEX (COVID/INFLUENZA A/B AND RSV), HELICOBACTER PYLORI (H. PYLORI) AND HEPATOCELLULAR CARCINOMA (HCC). THE CELIAC, RESPIRATORY MULTIPLEX AND H. PYLORI TESTS HAVE CE MARKS AND ARE ELIGIBLE TO BE SOLD IN EUROPE AT THE PRESENT TIME.

HEPION PHARMACEUTICALS EXECUTES BINDING LETTER OF INTENT WITH NEW DAY DIAGNOSTICS TO COMMERCIALIZE DIAGNOSTIC TESTS FOR CELIAC DISEASE, RESPIRATORY MULTIPLEX, H. PYLORI AND HCC

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (NYSE: HCC) (WARRIOR OR THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE FIRST QUARTER OF 2025. WARRIOR IS THE LEADING DEDICATED U.S.-BASED PRODUCER AND EXPORTER OF HIGH-QUALITY STEELMAKING COAL FOR THE GLOBAL STEEL INDUSTRY. WARRIOR REPORTED A NET LOSS FOR THE FIRST QUARTER OF 2025 OF $8.2 MILLION, OR $0.16 PER DILUTED SHARE, A DECREASE FROM NET INCOME OF $137.0 MILLION, OR $2.62 PER DILUTED SHARE, IN THE FIRST QUARTER OF 2024. THE COMPA.

WARRIOR REPORTS FIRST QUARTER 2025 RESULTS

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (NYSE:HCC) (WARRIOR OR THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED A REGULAR QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE TO BE PAID ON MAY 12, 2025, TO STOCKHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON MAY 5, 2025. ABOUT WARRIOR WARRIOR IS A U.S.-BASED, ENVIRONMENTALLY, AND SOCIALLY MINDED SUPPLIER TO THE GLOBAL STEEL INDUSTRY. IT IS DEDICATED ENTIRELY TO MINING NON-THERMAL METALLURGICAL (MET) COAL USED AS.

BROOKWOOD, ALA.--(BUSINESS WIRE)--WARRIOR MET COAL, INC. (WARRIOR OR NYSE: HCC) TODAY ANNOUNCED THAT IT WILL HOLD ITS FIRST QUARTER 2025 INVESTOR CONFERENCE CALL AT 4:30 P.M. ET ON WEDNESDAY, APRIL 30, 2025. WARRIOR WILL RELEASE ITS RESULTS FOLLOWING THE CLOSE OF MARKET TRADING THAT AFTERNOON. TO PARTICIPATE IN THE CONFERENCE CALL, PLEASE CALL 1-844-340-9047 (DOMESTIC) OR 1-412-858-5206 (INTERNATIONAL) 10 MINUTES PRIOR TO THE START TIME AND REFERENCE THE WARRIOR MET COAL CONFERENCE CALL. A WE.

Warrior Met Coal, Inc.

HCC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Warrior Met Coal, Inc.

HCC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

HCC